Overview

Everolimus Versus Placebo in Head and Neck Cancer

Status:
Terminated

Trial end date:
2018-10-01

Target enrollment:

Participant gender:

Summary

Primary: Two-year progression-free (tumor does not grow or spread) survival in subjects treated with everolimus versus placebo after definitive local therapy.

Phase:

Phase 2

Details

Lead Sponsor:

University of Chicago

Collaborator:

Novartis Pharmaceuticals

Treatments:

Everolimus
Sirolimus